Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05931887 · ClinicalTrials.gov registry record · NA
Evaluation of the Novel Silq ClearTract Catheter in Patients With Chronic Urinary Retention
A NA study of Catheter Infection and Catheter Related Complication, sponsored by Silq Technologies Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT05931887: Recruiting NA study of Catheter Infection and Catheter Related Complication, sponsored by Silq Technologies Corporation.
NCT05931887 is a NA study of Catheter Infection and Catheter Related Complication that is actively recruiting participants, run by Silq Technologies Corporation. The registered enrollment target is 200 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05931887, a NA study of Catheter Infection and Catheter Related Complication, is actively recruiting participants, sponsored by Silq Technologies Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the ability of the Silq ClearTract™ 100% Silicone 2-Way Foley Catheter to reduce catheter associated complications in subjects that require a long-term indwelling Foley catheter when compared to other commercially available Foley catheters.
Primary Outcome
Catheter Related Complications can be classified as: i. Symptomatic Catheter Associated Urinary Tract Infection ii. Catheter Blockage iii. General Premature Interventions: Patient sought care for a catheter-related issue prior to their scheduled catheter exchange
Conditions Studied
Interventions
- DEVICE SILQ ClearTract 100% Silicone 2-Way Foley Catheter
Study Locations (1)
California
- Rancho Los Amigos National Rehabilitation Center - Downey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2025-07-26 |
| Phase | NA |
What NCT05931887 shows while recruiting
NCT05931887 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Catheter Infection appearing as the primary indexed condition, and to 1 intervention - of which SILQ ClearTract 100% Silicone 2-Way Foley Catheter is the first listed.
NCT05931887 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05931887 about?
NCT05931887 is a clinical study titled "Evaluation of the Novel Silq ClearTract Catheter in Patients With Chronic Urinary Retention". To assess the ability of the Silq ClearTract™ 100% Silicone 2-Way Foley Catheter to reduce catheter associated complications in subjects that require a long-term indwelling Foley catheter when compared to other commercially available Foley catheters.
What is the current status of trial NCT05931887?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2023-07-26. Estimated completion is 2025-07-26.
What conditions does trial NCT05931887 study?
This clinical trial studies the following conditions: Catheter Infection, Catheter Related Complication, Catheter Blockage, Catheter Calcification.
What interventions are being tested in trial NCT05931887?
The interventions under investigation include: SILQ ClearTract 100% Silicone 2-Way Foley Catheter (DEVICE).
Who is sponsoring clinical trial NCT05931887?
This trial is sponsored by Silq Technologies Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05931887 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Catheter Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05931887's enrollment target sits among peer trials
200 506th of 2000 higher than 1,435 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI